ASH 2024 preview – CD19 back on the agenda
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
Car-T comes full circle
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
